EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitSystematische Übersicht

Androgen Receptor‐Targeted Therapy for Salivary Gland Carcinoma: Systematic Review and Meta‐Analysis

J Walker Rosenthal iD, David Z Allen, Jordan Sternthal, Isabella Romeo, Gurel Ari, Brianna Brammer, Erin E Reardon, Jose A Monteiro de Oliveira Novaes, Nabil F Saba, Jennifer Gross, Nicole C Schmitt iD

The Laryngoscope · 02.11.2026

DOI: 10.1002/lary.71034 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The Laryngoscope, online erschienen am 02.11.2026. Verfasst von J Walker Rosenthal und 10 weiteren Autor:innen. Beteiligte Einrichtung: Emory University School of Medicine, Atlanta, Georgia, USA. Die Arbeit nennt 48 Literaturangaben. Gefördert von: NIDCD NIH HHS, National Institute on Deafness and Other Communication Disorders.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Salivary duct carcinoma (SDC) is a rare and aggressive malignancy with limited effective treatment options in the recurrent/metastatic setting. Biologically, SDC has high rates of androgen receptor (AR) expression, providing a strong rationale for AR‐targeted therapy. Data Sources Ovid MEDLINE, Embase.com , Scopus, Web of Science, Cochrane Library, and ClinicalTrials.gov from their inception to August 20, 2026. Review Methods We conducted a systematic review and meta‐analysis of AR‐targeted therapy in patients with AR‐positive recurrent/metastatic SDC and SDC‐enriched salivary gland carcinoma cohorts. The primary outcome was overall response rate (ORR). Secondary outcomes included clinical benefit rate (CBR), progression‐free survival (PFS), and overall survival (OS). Pooled proportions were calculated using a random‐effects model. Combined androgen blockade was compared to AR‐targeted monotherapy.

Results

Twelve studies were included in the systematic review accounting for 587 eligible patients. The primary meta‐analysis has 10 eligible studies (417 patients). The pooled ORR was 26.6% (95% CI, 15.4%–42.1%). Five studies reported CBR, and the pooled CBR was 45.0% (95% CI, 38.1%–52.1%). The sample‐size‐weighted mean of reported median PFS was 6.3 months, and the weighted mean of reported median OS was 26.9 months among the seven studies reporting OS. ORR was higher with combined androgen blockade than with AR‐targeted monotherapy (36.3% vs. 8.9%; meta‐regression p = 0.023).

Conclusion

AR‐targeted therapy shows clinically meaningful activity in AR‐positive disease, particularly with combined androgen blockade. The evidence remains heterogeneous and largely nonrandomized, so treatment decisions should account for HER2 status, AR expression level, treatment line, and patient tolerance.

Schlagwörter

Stichwörter der Autor:innen

androgen deprivation therapyandrogen receptorcombined androgen blockademeta‐analysissalivary duct carcinoma

Autor:innen und Institutionen

  • Emory University School of Medicine, Atlanta, Georgia, USA.
  • Department of Otolaryngology Head and Neck Surgery and Winship Cancer Institute, Emory University, Atlanta, Georgia, USA.
  • Department of Hematology and Medical Oncology and Winship Cancer Institute, Emory University, Atlanta, Georgia, USA.

ORCID-Profile: J Walker Rosenthal, Nicole C Schmitt

Förderung

  • NIDCD NIH HHS
  • National Institute on Deafness and Other Communication Disorders

Zitieren

APA

Rosenthal, J. W., Allen, D. Z., Sternthal, J., Romeo, I., Ari, G., Brammer, B., Reardon, E. E., Novaes, J. A. M. O., Saba, N. F., Gross, J., & Schmitt, N. C. (2026). Androgen Receptor‐Targeted Therapy for Salivary Gland Carcinoma: Systematic Review and Meta‐Analysis. The Laryngoscope. https://doi.org/10.1002/lary.71034

Vancouver

Rosenthal JW, Allen DZ, Sternthal J, Romeo I, Ari G, Brammer B, et al. Androgen Receptor‐Targeted Therapy for Salivary Gland Carcinoma: Systematic Review and Meta‐Analysis. The Laryngoscope. 2026. doi:10.1002/lary.71034

BibTeX
@article{Rosenthal2026,
  author = {Rosenthal, J Walker and Allen, David Z and Sternthal, Jordan and Romeo, Isabella and Ari, Gurel and Brammer, Brianna and Reardon, Erin E and Novaes, Jose A Monteiro de Oliveira and Saba, Nabil F and Gross, Jennifer and Schmitt, Nicole C},
  title = {Androgen Receptor‐Targeted Therapy for Salivary Gland Carcinoma: Systematic Review and Meta‐Analysis},
  journal = {The Laryngoscope},
  year = {2026},
  doi = {10.1002/lary.71034}
}
Kostenlos starten →